42nd week of 2010 patent applcation highlights part 36 |
Patent application number | Title | Published |
20100266604 | USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS - This disclosure concerns compositions and methods for immunoenhancement and/or immunosuppression. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor for immunoenhancement, for example as a vaccine adjuvant, for the treatment of sepsis, or for treating an immunocompromised subject. Also disclosed are methods of screening for immunoenhancing agents. In other embodiments, the disclosure concerns methods of using a TAM receptor agonist for immunosuppression, for example as a treatment for an autoimmune disorder, for the treatment of an allergy, or for treating graft-versus-host disease in a subject. Also disclosed are methods of screening for immunosuppressive agents. | 2010-10-21 |
20100266605 | USE OF A CD28 BINDING PHARMACEUTICAL SUBSTANCE FOR MAKING A PHARMACEUTICAL COMPOSITION WITH DOSE-DEPENDENT EFFECT - The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit. | 2010-10-21 |
20100266606 | ANTIBODY THERAPY FOR HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS - The present invention relates to a monoclonal antibody against hemagglutinin of highly pathogenic avian influenza virus subtype H5 or functional fragment thereof, a hybridoma producing the monoclonal antibody, and a composition comprising the monoclonal antibody or functional fragment thereof. In addition, the present invention relates to a method for preventing or treating influenza virus infection by administering the composition to a subject, and an assay kit for influenza virus comprising the monoclonal antibody or functional fragment thereof. | 2010-10-21 |
20100266607 | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 2010-10-21 |
20100266608 | IL-17 Antagonistic Antibodies - An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of a solid or hematological malignant diseases. | 2010-10-21 |
20100266609 | Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2010-10-21 |
20100266610 | AUTO-ANTIBODY MARKERS OF AUTOIMMUNE DISEASE - The present invention encompasses auto-antibodies associated with autoimmune disorders. The auto-antibodies may be used, for example, in methods of treating patients, methods of diagnosing patients, methods of monitoring disease progression of patients, and methods of prognosing patients. | 2010-10-21 |
20100266611 | Enhancement of Immune Responses By 4-1BB-Binding Agents - This invention features methods of enhancing immune responses in mammalian subjects and in vitro methods of enhancing the response of a T cell. Also embodied by the invention are methods of receiving and preventing the induction of energy in T cells. | 2010-10-21 |
20100266612 | BMP-ALK3 ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins. | 2010-10-21 |
20100266613 | ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES - The present invention relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of TNF-α. | 2010-10-21 |
20100266614 | ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES - Ultra high affinity antibodies with binding affinities in the range of 10 | 2010-10-21 |
20100266615 | D1-1 NUCLEIC ACIDS, POLYPEPTIDES AND RELATED METHODS - The disclosure provides, among other things, novel angiogenesis-related nucleic acids, polypeptides and methods of use. | 2010-10-21 |
20100266616 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD. | 2010-10-21 |
20100266617 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 - Antibodies which block the binding of human Programmed Death Receptor 1(hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed. | 2010-10-21 |
20100266618 | COMPOSITIONS AND METHODS FOR AUGMENTING ACTIVITY OF ONCOLYTIC VIRUSES - Disclosed are compositions and methods for augmenting activity of oncolytic viruses. Virus activity is augmented by sensitizing cancer or tumour cells through modulation of the Endoplasmic Reticulum (ER) stress response pathway, for instance by introducing into a tumour cell an agent effective to modulate ER stress response and sensitize the tumour cell. The tumour cells are then contacted with an oncolytic virus in an amount effective to reduce viability of the sensitized tumour cell. The oncolytic virus is thereby rendered more effective at lysing or killing the sensitized tumour or cancer cells. | 2010-10-21 |
20100266619 | Neutralizing Antibodies and Methods of Use Thereof - This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies. | 2010-10-21 |
20100266620 | Immunoconjugates for treatment of infectious diseases - The present invention features immunoconjugates which comprise therapeutic agents coupled to antibodies that specifically recognize pathogen surface antigens. These immunoconjugates can be used to treat or prevent infectious diseases. Upon administration of an immunoconjugate of the present invention to an infected host, the immunoconjugate binds to a specific antigen on the surface of the targeted pathogen (e.g., virus). As the pathogen enters the host cells, the therapeutic agent(s) in the immunoconjugate destroys the infected host cells (and, preferably, the bound pathogen), thereby preventing the replication and transmission of the pathogen. In one embodiment, the immunoconjugates of the present invention specifically recognize surface/envelope antigens of the following viruses: HIV, HBV, HCV, EBV, influenza virus, and SARS associated coronavirus. | 2010-10-21 |
20100266621 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES - Psoralen compounds of Formula (I): | 2010-10-21 |
20100266622 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 2010-10-21 |
20100266623 | SYNTHETIC, SELF ADJUVANTING VACCINES - The present invention relates generally to the field of immunotherapy, and more particularly to immunomedicaments in the form of lipopeptides which induce an antibody response to drugs of dependence, and uses thereof in the treatment and prevention of drug addiction. | 2010-10-21 |
20100266624 | HEPATITIS-C VIRUS TESTING - New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping. | 2010-10-21 |
20100266625 | Meningococcal and Pneumococcal Conjugate Vaccine and Method of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both | 2010-10-21 |
20100266626 | ADJUVANTED GLUCANS - The use of beta-glucans as antigens for immunising against fungi is known. According to the invention, the beta-glucans are administered together with an adjuvant. The adjuvant improves the immune response. The glucan will usually be conjugated to a carrier. Suitable glucans include laminarin and curdlan. | 2010-10-21 |
20100266627 | ALLELIC EXCHANGE MUTAGENESIS IN MAP - Particular aspects provide efficient allelic exchange methods to generate directed mutations within genes of slow-growing stains of mycobacteria (e.g., | 2010-10-21 |
20100266628 | MACROCYCLIC LACTONE COMBINATION COMPOSITIONS, VACCINES AND METHODS FOR PRODUCING SAME - An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues. | 2010-10-21 |
20100266629 | Cattle Reproductive Disease Vaccines - The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI | 2010-10-21 |
20100266630 | Recombinant MVA virus, and the use thereof - The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines. | 2010-10-21 |
20100266631 | Compositions and Methods for Generating an Immune Response Utilizing Alphavirus-Based Vector Systems - Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses. | 2010-10-21 |
20100266632 | VACCINE COMPOSITION COMPRISING AN IMMUNOADJUVANT COMPOUND CONSISTING OF A RHO GTPASE FAMILY ACTIVATOR - An immunogenic or vaccine composition comprising an immunoadjuvant compound consisting of a Rho GTPase activator. The Activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. | 2010-10-21 |
20100266633 | AIDS VIRUS VACCINES USING SENDAI VIRUS VECTOR - The present invention provides a vaccine containing a Sendai virus vector encoding a virus protein of an immunodeficiency virus. By intranasally administering a Sendai virus encoding a virus protein of an immunodeficiency virus to a macaque monkey, the present inventors have succeeded in efficiently inducing protective immunity against an immunodeficiency virus. As a result of intranasal inoculation of vaccine, expression of an antigen protein mediated by Sendai virus vector was detected in intranasal mucous membrane and local lymph nodes and antigen-specific cellular immune response was induced at a significant level. No pathological symptom by vaccination was observed. After vaccination, exposure of simian immunodeficiency virus was performed and the effect was examined. As a result, the amount of virus in plasma significantly decreased, compared with that of the control animal. The present invention provides a promising vaccine as an AIDS vaccine. | 2010-10-21 |
20100266634 | ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS - The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety. | 2010-10-21 |
20100266635 | HIVCON: AN HIV IMMUNOGEN AND USES THEREOF - The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial sequences. HIVCON is an AFP in which the HIV domains are from several HIV Glade consensus sequences and which optionally contains additional domains which may be useful, for example, in monitoring expression levels or laboratory animal immune responses. Other aspects of the invention may include compositions and methods for inducing an anti-HIV immune response in a subject, preferably with a DNA prime-MVA boost strategy, and to induce a cell-mediated immune response. | 2010-10-21 |
20100266636 | METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS - The present invention relates to vaccine compositions comprising | 2010-10-21 |
20100266637 | METHOD OF PREVENTING EARLY LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates inter alia to the use of a combination of a vaccine against | 2010-10-21 |
20100266638 | HEADACHE TREATMENT METHOD - Herein disclosed are methods for treating headache, such as a chronic migraine for example, by administration of | 2010-10-21 |
20100266639 | Expression system - An immunogenic reagent which produces an immune response which is protective against | 2010-10-21 |
20100266640 | Plant-Derived Cholera and Malaria Vaccine - Described herein are methods for simultaneously immunizing a subject against Cholera and Malarial infection. Specifically exemplified herein are methods that involve administering compositions comprising a CTB-AMA1 or CTB-MSP1 derived from plants having plastids transformed to express such conjugates. | 2010-10-21 |
20100266641 | Endophytic Fungi from Pteromischum Sp. Plant, Compounds and Methods of Use - The present disclosure relates to endophytic fungi from higher plants such as a | 2010-10-21 |
20100266642 | MODIFIED CELLS FOR TARGETED CELL TRAFFICKING AND USES THEREOF - This application provides methods of making modified cells containing pre-functionalized poly(ethylene glycol) (PEG) and/or other pre-functionalized polymers are provided. The modified cells produced according to the disclosed methods as well as their use in the treatment of various diseases are also provided. | 2010-10-21 |
20100266643 | PULMONARY AND NASAL DELIVERY OF SERUM AMYLOID P - The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided. | 2010-10-21 |
20100266644 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON - The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof. | 2010-10-21 |
20100266645 | PHARMACEUTICAL COMPOSITIONS - Provided herein are formulations and methods for treating pain in human beings. Also provide are optimal ratios at which an opioid and an opioid antagonist may be combined for administration to humans such that the opioid activity is inhibited. These ratios may also be used to formulate compositions containing both an opioid and an opioid antagonist within a single pharmaceutical dosing unit. | 2010-10-21 |
20100266646 | Assemblies, systems, and methods for skin treatment incorporating oxidized cellulose - A refined oxidised cellulose (OC) material in various salt states having therapeutic treatments for skin. The micronized OC has a uniform particle size of the order of microns (0.001 to 0.050 mm). The OC is treated by further steps of oxidation, hydrolysis and refinement. The final product is chemically known as polyanhydroglucuronic acid, (PAGA). The salt versions of the OC are generally metal salts, such as sodium, calcium, zinc, copper, and silver. | 2010-10-21 |
20100266647 | Optical Blurring Pigment Composition Suitable for Use in Cosmetics - Compositions comprising a gel system made from a combination of a fractal network of nanoparticles and translucent macroscopic particles, titanium dioxide and other color pigments is disclosed. The compositions are capable of forming an effective film on the biological surface such as skin to blurring fine lines and wrinkles while retaining a natural look of the skin as a consequence of synergy between the fractal particles, the macroscopic particles, titanium dioxide and color pigments. Also disclosed methods for their use. | 2010-10-21 |
20100266648 | Cosmetic Compositions for Imparting Superhydrophobic Films - Compositions and methods are disclosed for imparting super-hydrophobic properties to cosmetics, which can be used to significantly improve water repellency compared to traditional cosmetics. The compositions comprise a hydrophobic film former, and hydrophobic particles, in an emulsion base. | 2010-10-21 |
20100266649 | Gel Technology Suitable for Use in Cosmetic Compositions - A gel system comprising a fractal network of nanoparticles and macroscopic particles is disclosed. The gel system is capable of forming an “optical gel” effective to blurrfine lines and wrinkles as a consequence of the size domain differences between the fractal particles and the macroscopic particles. Cosmetic compositions comprising such gels and methods for their use are also disclosed. | 2010-10-21 |
20100266650 | METHOD OF COSMETIC CARE STIMULATING MITOCHONDRIAL ACONITASE - The invention relates to the use of a plant extract as a cosmetic agent. | 2010-10-21 |
20100266651 | EMULSIFIER INCLUDING GLYCERIN-MODIFIED ORGANOPOLYSILOXANES - The invention relates to emulsifiers comprising glycerin-modified organopolysiloxanes and to their use for the preparation of extraordinarily stable emulsions and dispersions. | 2010-10-21 |
20100266652 | SLOW RELEASE BIOCIDAL THERMOPLASTIC COMPOSITIONS AND ARTICLES - In one aspect, the invention is directed to a biocidal composition, comprising a mixture of a substantially oxidation-resistant thermoplastic polymer having a melting point of about 60° C. to about 100° C.; and a composition for releasing chlorine dioxide gas upon exposure to moisture and having a bulk density less than about 0.15 g/cc, wherein the mixture of the first thermoplastic polymer and the gas releasing composition has a higher bulk density than gas releasing composition and is a substantially free-flowing non-dusting powder. In another aspect, the invention provides a polymeric matrix comprising the biocidal composition and a second thermoplastic polymer. Both the biocidal composition and the biocidal composition in the polymeric matrix are suitable for commercial manufacture of extruded, injection molded or blow molded articles, films, sheets, and the like. | 2010-10-21 |
20100266653 | BIOCIDAL POLYACROLEIN COMPOSITION - This invention relates to a biocidal composition comprising fine particles comprising polyacrolein wherein at least 90% of particles are of a size no more than 30 microns. Preferably at least 90% of particles are of size no more than 5 microns and still more preferably at least 90% of particles are of size no more than 1 micron. | 2010-10-21 |
20100266654 | MEDICAL COMPOSITION INCLUDING AN EXTRACELLULAR MATRIX PARTICULATE - Described are medical compositions including a collagenous ECM particulate dispersed in a carrier. Such medical compositions can be applied to at least a portion of a surface of a sheet of collagenous ECM material to form a medical product. Medical compositions and products as described herein find particular use in wound repair. Related methods of manufacture and use are also described. | 2010-10-21 |
20100266655 | SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUNDS - The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof. | 2010-10-21 |
20100266656 | Splittable Elastomeric Drug Delivery Device - A system for treating a vascular condition including a catheter and a splittable elastomeric drug delivery device. The splittable elastomeric drug delivery device includes a balloon disposed on the catheter. The balloon includes a first elastic layer and a second elastic layer. A therapeutic agent layer is disposed on at least a portion of the first elastic layer, and the second elastic layer is disposed on the first elastic layer and the therapeutic agent layer. The first elastic layer has a first elongation-at-break percentage and the second elastic layer has a second elongation-at-break percentage. | 2010-10-21 |
20100266657 | PREFORMED DRUG-ELUTING DEVICE TO BE AFFIXED TO AN ANTERIOR SPINAL PLATE - A drug-eluting device comprising a drug-eluting matrix containing at least one elutable drug, a method of manufacturing a preformed drug-eluting device, and an implant kit comprising the same. | 2010-10-21 |
20100266658 | Osteogenic Implants with Combined Implant Materials and Methods for Same - Described are osteogenic implants that include a first implant material covered at least in part by a second implant material carrying an osteogenic protein such as a bone morphogenic protein. The first implant material can comprise a mineral and provide an inner scaffolding portion for supporting bone ingrowth, and the second implant material can comprise a collagen or other sponge carrier covering the first implant material and having a liquid osteogenic protein formulation imbibed therein. Related implant materials and methods of preparation and use constitute additional aspects of the invention. | 2010-10-21 |
20100266659 | IMPLANTABLE DEVICES FORMED ON NON-FOULING METHACRYLATE OR ACRYLATE POLYMERS - Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof. | 2010-10-21 |
20100266660 | Osteogenic Implants with Combined Implant Materials and Methods for Same - Described are osteogenic implants that include a first implant material covered at least in part by a second implant material carrying an osteogenic protein such as a bone morphogenic protein. The first implant material can comprise a mineral and provide an inner scaffolding portion for supporting bone ingrowth, and the second implant material can comprise a collagen or other sponge carrier covering the first implant material and having a liquid osteogenic protein formulation imbibed therein. Related implant materials and methods of preparation and use constitute additional aspects of the invention. | 2010-10-21 |
20100266661 | OSTEOGENIC IMPLANTS WITH COMBINED IMPLANT MATERIALS AND METHODS FOR SAME - Described are osteogenic implants that include a first implant material covered at least in part by a second implant material carrying an osteogenic protein such as a bone morphogenic protein. The first implant material can comprise a mineral and provide an inner scaffolding portion for supporting bone ingrowth, and the second implant material can comprise a collagen or other sponge carrier covering the first implant material and having a liquid osteogenic protein formulation imbibed therein. Related implant materials and methods of preparation and use constitute additional aspects of the invention. | 2010-10-21 |
20100266662 | METHODS OF PROMOTING ENHANCED HEALING OF TISSUES AFTER CARDIAC SURGERY - Resorbable polylactide polymer healing membranes and methods of their applications are disclosed. In a broad embodiment, the invention features methods for inducing proper tissue healing after an open heart surgery. In one embodiment, the methods includes a step of forming a patch with a healing membrane over the open pericardium to induce proper tissue healing and placement in other open heart surgery procedures to facilitate re-entry by the surgeon. | 2010-10-21 |
20100266663 | TISSUE-TREATING IMPLANTABLE COMPOSITIONS - A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being exposed substantially only to the host's subcutaneous tissue layer. This orientation allows the tissue-ingrowth biodegradable region to become firmly incorporated with the host's body tissue. The adhesion-resistant biodegradable region faces the internal organs and decreases the incidence of adhesions and/or bowel obstruction. | 2010-10-21 |
20100266664 | Devices And Methods For Ophthalmic Drug Delivery - Disclosed are ophthalmic drug-delivery devices, comprising a body having a proximal end and a distal end, wherein the body includes a styrene elastomer matrix and a drug in contact with the matrix. Also disclosed are methods of treating or preventing an eye disease in a subject, that involve contacting an eye of the subject with an ophthalmic drug delivery device comprising a body having a proximal end and a distal end, wherein the body comprises a styrene elastomer matrix and a drug in contact with the matrix, wherein release of the drug from the device occurs over time following contacting of the device with the eye of the subject. | 2010-10-21 |
20100266665 | Fenugreek Flour for Incorporating Into Food Products - A process for obtaining fenugreek flour from fenugreek seeds has been developed, and the flour incorporated into baked or other food products. The processed fenugreek flour from boiled seeds was easier to add into food products than whole seeds and did not compromise the food's taste or texture. This fenugreek flour can be included in everyday food items and will allow increased use in fenugreek to aid in the prevention of diabetes and obesity. Using this flour, a fenugreek bread formula was developed, and the bread was produced in a commercial bakery by incorporating fenugreek flour into a standard wheat bread formula. Eight diet controlled diabetic subjects were served wheat bread with about 5% fenugreek, and the consumption of the fenugreek bread was shown to reduce serum insulin indicating the bioactivity of the fenugreek remained in the bread. | 2010-10-21 |
20100266666 | Chewing Gum Tablet And Method Of Dosing Pharmaceutically Active Ingredients In Such Chewing Gum Tablet - A method of dosing pharmaceutically active ingredients in a compressed chewing gum tablet includes the steps of: providing one or more pharmaceutically active ingredients, mixing a chewing gum composition including the one or more pharmaceutically active ingredients and chewing gum granules, the chewing gum granules including gum base, and dosing the chewing gum composition to obtain a desired weight of the chewing gum composition and thereby obtaining a desired dose of the pharmaceutically active ingredient in the chewing gum tablet. | 2010-10-21 |
20100266667 | MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES - A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation. | 2010-10-21 |
20100266668 | Manufacturing Dissolvable Dosage Forms - A method of manufacturing a dosage form is described wherein a liquid solution of a biologically compatible polymer containing a suspension of particulate material that is insoluble in the polymer is supplied to a liquid supply tube ( | 2010-10-21 |
20100266669 | MULTI-ZONE FILMS - The invention relates to single-layer oral disintegrating films having at least two distinct zones, which comprise nicotine and allow for effective buccal (=oral mucosal) absorption thereof. | 2010-10-21 |
20100266670 | TRANSDERMALLY ABSORPTIVE PREPARATION - This invention is to provide a transdermal administration type pharmaceutical preparation which has better transdermal absorptivity, safety and practical application for treatment of bone calcium metabolic diseases, such as high calcium in blood which resulted from osteoporosis, osteitis deformans and malignant tumors. | 2010-10-21 |
20100266671 | Device and Method for Treating Dermal Tissue - The present disclosure provides gel compositions useful for treating the skin. The gel compositions are hydrogels that include from about 33 wt % to about 68 wt % of a humectant or a mixture of humectants; about 0 wt % to about 8 wt % of an electrolyte or mixture of electrolytes; from about 2 wt % to about 20 wt % of water; from about 18 wt % to about 45 wt % of a copolymer. The copolymer includes, in polymerized form, from about 80 mol % to about 95 mol % of a first monomer, which is a mixture of acrylic acid and a salt thereof, from about 5 mol % to 20 mol % of a second monomer, which can be a salt of 2-acrylamido-2-methylpropane sulfonic acid, and, optionally a crosslinking agent. In embodiments, the gel composition has a pH of about 7.0 or less. The dermal patches of the present disclosure may be utilized in skin care, and may include the application of the patch, its removal, and re-application to tissue. | 2010-10-21 |
20100266672 | VACCINES - The present invention provides a vaccine composition comprising the B subunit of Shiga toxin or an immunologically functional equivalent thereof which is able to bind the Gb3 receptor, complexed with at least one first antigen, and further comprising at least one second antigen (which may be the same or different as the first antigen) and an adjuvant. | 2010-10-21 |
20100266673 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NITRIC OXIDE - H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or 0 | 2010-10-21 |
20100266674 | L-ODDC PRODRUGS FOR CANCER - The main drawback in the use of most nucleoside anticancer agents originates from their hydrophilic nature, of which property requires a high and frequent dosage for an intravenous administration. Unlike other nucleoside anti-tumor agents, troxacitabine appears to predominantly enter tumor cells by passive diffusion rather then by using nucleoside transporters, although this may be model dependent. Accordingly, in the present work, a small library of twenty troxacitabine prodrugs has been synthesized using a parallel approach in order to evaluate the relationship between the lipophilicity of the prodrugs and their antitumor activity. Biological evaluation of the prodrugs on two non-small cell lung cancer cell lines (A549 and SW1573) and in pancreatic cell lines clearly showed better antitumor activity than that of troxacitabine, with IC | 2010-10-21 |
20100266675 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM - The invention provides novel compositions—lipopeptides and analogs, including somocystinamide A, and somocystinamide A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these lipopeptides and analogs are used to induce apoptosis in a cell, which can be a normal cell, a dysfunctional cell and/or a cancer (tumor) cell. In alternative embodiments, the compositions of the invention, including the lipopeptides and analogs of the invention, and the pharmaceutical compositions comprising them, are used to treat or ameliorate (including slowing the progression of) normal, dysfunctional (e.g., abnormally proliferating) and/or tumor associated blood vessels, including endothelial and/or capillary cell growth; including neovasculature related to (within, providing a blood supply to) a tumor. | 2010-10-21 |
20100266676 | NANOCAPSULES WITH A LIQUID LIPID CORE CHARGED WITH WATER-SOLUBLE OR WATER-DISPERSIBLE ACTIVE AGENTS - The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system. | 2010-10-21 |
20100266677 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE - The present invention relates to homo- and hetero-dimer compounds formed by a disulfide, sulfinyl thio, or olefin bond between two monomers. A method of making a homo- or hetero-dimer compound is also disclosed. The present invention also relates to monomer compounds capable of forming homo- or hetero-dimer compounds, as well as oligomers formed via linkage of one or more dimers. Also disclosed are methods of inhibiting the activity of target RNA molecules, particularly those having a secondary structure that include a stem or stem-loop formation. Dimer compounds capable of inhibiting the activity of an HIV-I RNA frameshifting stem-loop and a (CUG)n expanded repeat stem-loop are disclosed, as are methods of treating diseases associated with these target RNA molecules. The dimer compounds can also be used for selectively detecting presence of the target RNA molecule in a sample. | 2010-10-21 |
20100266678 | CHOLESTEROL LEVEL LOWERING LIPOSOMES - Provided are methods of reducing cellular cholesterol levels using lipid particles that are capable of cellular entry. Such lipid particles may be used for treating or preventing a disease or condition that is caused by or associated with an increased cellular cholesterol level and for treating or preventing a disease or condition, that is caused by or associated with a virus, that relies on cellular cholesterol for its replication. | 2010-10-21 |
20100266679 | CRYSTALLINE MODIFICATIONS OF N-ALPHA-(2,4,6-TRIISOPROPYLPHENYLSULFONYL)-3-HYDROXYAMIDINO- (L)- PHENYLALANINE 4-ETHOXYCARBONYLPIPERAZIDE AND/OR SALTS THEREOF - The present invention relates to novel crystalline modifications of N-α-(2,4,6-triisopropylphenyl-sulfonyl)-3-hydroxyamidino-(L)-phenylalanine 4-ethoxy-carbonylpiperazide and/or salts thereof, which can be used as pharmaceutical agents, and to pharmaceutical compositions and pharmaceutical uses comprising these novel crystalline modifications. | 2010-10-21 |
20100266680 | Treatment of Cancer Using TLR3 Agonists - The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells. | 2010-10-21 |
20100266681 | FATTY ACID ALCOHOLS - The present invention relates to a lipid composition comprising at least omega-3 polyunsaturated alcohols, or pro-drugs thereof, which omega-3 polyunsaturated alcohols, or pro-drugs thereof, comprising at least (all-Z)-5,8,11,14,17-eicosapentaen-1-ol, or pro-drug thereof, and (all-Z)-4,7,10,13,16,19-docosahexaen-1-ol, or pro-drug thereof, and their use as a pharmaceutical, in particular for the treatment of elevated triglyceride levels. The invention also relates to methods for the preparation of these pro-drugs from marine oils. | 2010-10-21 |
20100266682 | POLYETHYLENE GLYCOL-COATED SODIUM CARBONATE AS A PHARMACEUTICAL EXCIPIENT AND COMPOSITIONS PRODUCED FROM THE SAME - Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle of carbonate coated by a layer of polyethylene glycol, and a second pH-modifying agent. The weakly basic therapeutic agent could be, but is not limited to, zolpidem or scopolamine. Compositions including zolpidem and scopolamine are used to treat insomnia and depression, respectively. | 2010-10-21 |
20100266683 | NEW SELF EMULSIFYING DRUG DELIVERY SYSTEM - The present invention claims and discloses a pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprising
| 2010-10-21 |
20100266684 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 2010-10-21 |
20100266685 | Seamless Coated Spherical Filled Capsules - Described is a spherical coated capsule comprising (a) a coating-free capsule having (i) a liquid or viscous core and (ii) a solid shell surrounding this core, and (b) a seamless, solid coating surrounding said coating-free capsule, wherein the diameter of the spherical coated capsule is in the greater than 9 mm, the solid coating comprises at least one sugar or sugar-alcohol in an amount in the range of 30-90% (m/m), based on the total mass of the coated capsule, the diameter of the coating-free capsule is in the range of 5-10 mm, the thickness of the shell of said coating-free capsule is in the range of 30-200 μm, the ratio of shell thickness diameter of said coating-free capsule is in the range of 0.004-0.04, the shell of said coating-free capsule contains 70-90% (m/m) gelatine or alginate and 10-30% (m/m) plasticiser, based on the dry mass of said shell, and the core has a flavouring content in the range of 1-100% (m/m), based on the total mass of the core. Further described is a method for preparing such capsule. | 2010-10-21 |
20100266686 | ANTI-AMYLOID ANTIBODIES AND THEIR USE IN DIAGNOSIS AND THERAPY OF AMYLOID DISEASES - The invention concerns antibodies to amyloid fibrillar and non-fibrillar polypeptides. The invention further concerns the use of such antibodies in diagnosis, treatment and/or prevention of amyloid diseases. The present invention also provides preparations and methods for preventing and treating, in a mammal, a disease characterized by amyloid formation and/or aggregation, preferably by promoting a non-fibrillar aggregation. | 2010-10-21 |
20100266687 | IMPROVED TABLET COATING - The present invention provides a tablet coating composition including a cellulose polymer, a plasticiser, a sweetener, and a powdered flavour composition. The powdered flavour composition includes a flavourant associated with a solid carrier. The present invention also provides a pharmaceutical tablet including a core containing an active agent and a coating formed from the tablet coating composition. | 2010-10-21 |
20100266688 | ANTI-BACTERIAL COMPOSITION AND METHOD FOR PRODUCING THE SAME - The invention discloses an anti-bacterial composition and method for producing the same. The anti-bacterial composition of the invention includes an organic siloxane material which comprises an amino group, and a plurality of silver atoms. Particularly, the organic siloxane material has a meshed structure, and the plurality of silver atoms are bonded to the amino group and are well dispersed in the meshed structure. | 2010-10-21 |
20100266689 | Tissue Augmentation With Active Agent For Wound Healing - The invention relates to a bioactive settable hydrogel matrix having a pore creating material, which may also carry a therapeutic agent, and methods of using the same, for example, use in promoting internal wound healing, tissue repair, tissue regeneration. | 2010-10-21 |
20100266690 | STABILIZER CONCENTRATE FOR MATRIX COMPOSITIONS PROCESSED AT ELEVATED TEMPERATURES - A stabilizer concentrate of, by wt. (a) 5 to 50% of N-(trichloromethylthio)phthalimide, (b) 5-20% antioxidant, and optionally (c) a carrier component. The concentrate can be incorporated into a matrix composition, e.g., a plastic, and processed at temperatures up to 2800 C without degrading the biocide or discoloring the plastic. | 2010-10-21 |
20100266691 | Agents and Methods to Stimulate Bone Healing - An agent for stimulating bone healing including isolated lysophosphatidic acid (LPA) and a hydrogel. A method of enhancing bone healing including identifying a damaged area of a bone and administering an agent comprising lysophosphatidic acid (LPA) is administered to the damaged area of the bone. A method of increasing bone regrowth. A subject is identified having a bone injury and lysophosphatidic acid (LPA) is administered to the subject. | 2010-10-21 |
20100266692 | NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN ANIONIC CELLULOSIC POLYMER - A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an anionic cellulosic polymer. | 2010-10-21 |
20100266693 | Controlled release local anesthetic comprising a biologically active non-sulfated glycosaminoglycan matrix - The invention relates to structuring a combination of bioactive materials that are capable of controlled extended release of local anesthesia lasting over 30 hours. | 2010-10-21 |
20100266694 | Chitosan/Carbon Nanotube Composite Scaffolds for Drug Delivery - A novel composite for internal application within wounds, incisions, and the like, for the prevention of biofilm growth therein is provided. Such a composite includes an antibiotic introduced within a sponge-like chitosan delivery product with electrically conductive nanomaterials present. Such a delivery product is also lyophilized subsequent to nanomaterial introduction but prior to antibiotic inclusion. The inventive lyophilized composite permits delivery of needed antibiotics internally within a patient with the simultaneous exposure to a sufficiently strong electrical current to permit a synergistic effect of increased antibiotic efficacy. In such a manner, relatively low amounts of antibiotic may be utilized to reduce the propensity of biofilm formation and/or growth within a wound or incision, or on the surface of an implant. Additionally, the lyophilized chitosan/nanomaterial composite allows for a maximum amount of antibiotic to be introduced with maximum elution therefrom as well. Lastly, the chitosan degrades over time within the subject's body, thereby avoiding any further invasive removal procedures. The method of such a manner of delivering improved antibiotic efficacy for biofilm prevention is encompassed within this invention as well. | 2010-10-21 |
20100266695 | MULTIVALENT CLUSTERING TARGETING STRATEGY FOR DRUG CARRIERS - The present invention provides clustered ligand vehicles for the delivery of a nucleic acid therapeutic agent to a target expressing a receptor. The invention further provides methods for treating a disease state by targeting a nucleic acid therapeutic agent to a target expressing a receptor using clustered ligand vehicles. | 2010-10-21 |
20100266696 | Organic Compounds - A process of preparing a particulate and substantially crystalline drug substance. The process involves suspending a substantially crystalline drug substance in an anti-solvent to give a suspension, homogenising the suspension at elevated pressure to give drug particles that have a mean particle size of less than about 10 μm, and drying the drug particles to remove any residual anti-solvent. | 2010-10-21 |
20100266697 | MIXED LIGAND SURFACE-MODIFIED NANOPARTICLES - A composition comprises surface-modified nanoparticles of at least one amphoteric metal oxide or oxyhydroxide. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising (i) at least one surface modifier selected from lactate, thiolactate, and mixtures thereof, and (ii) at least one surface modifier selected from halide, nitrate, acetate, carbonate, formate, propionate, sulfate, bromate, perchlorate, tribromoacetate, trichloroacetate, trifluoroacetate, carboxylate comprising from one to about four alkyleneoxy moieties, chlorate, and mixtures thereof. | 2010-10-21 |
20100266698 | USE OF INSULIN FOR THE TREATMENT OF CARTILAGINOUS DISORDERS - The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of chondrocytes previously treated with an effective amount of insulin and/or insulin variant. | 2010-10-21 |
20100266699 | Pharmaceutical Suspensions and Related Methods - A pharmaceutical suspension having a therapeutically effective amount of phenylephrine and a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; wherein the pharmaceutical suspension has a pH of from about 4 to about 6 and is substantially free of a reducing sugar and related methods. | 2010-10-21 |
20100266700 | USE OF ADSORBENT CARBON MICROSPHERES FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME - Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome. | 2010-10-21 |
20100266701 | ANTI-MISUSE MICROPARTICULATE ORAL DRUG FORM - The invention relates to solid microparticulate oral dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient (API) contained therein. The aim of the invention is to prevent the improper use of solid oral drugs for any use other than the therapeutic use(s) officially approved by the appropriate public health authorities. Another aim of the invention is to provide novel analgesic drugs which can be used to: prevent the misuse of, and addiction to certain analgesics and/or to control plasma concentration variability and/or to facilitate oral; administration; and/or to combine analgesics with one another and/or with one or more active ingredients in the same oral form. More specifically, the invention relates to a solid oral drug form comprising anti-misuse means and at least one active ingredient, which is characterized in that: at least part of the active ingredient is contained in microparticles; and the anti-misuse means comprise anti-crushing means (a) which enable the microparticles of the active ingredient to resist crushing, such as to prevent the misuse thereof. According to the invention, the drug form can also comprise means (b) for preventing the misuse of the active ingredient following a possible liquid extraction process. | 2010-10-21 |
20100266702 | Particles containing an active agent in the form of a co-precipitate - The invention relates to particles containing an active agent in the form of a co-precipitate to a method for producing said particles and to pharmaceutical forms containing said particles. | 2010-10-21 |
20100266703 | NOVEL POWDER AND ITS METHOD OF MANUFACTURE - The invention relates to a novel powder, it's method of manufacture and the use thereof in powder material processing, particularly in the manufacture of components formed from compacted powder e.g. discs, monoliths, layers or tablets. The powders comprise coated host particles wherein over 70% of the mass of the powder comprises coated particles smaller than 100 microns. The powders have particular application in the pharmaceutical industry and the technology described can be used to control the properties of active pharmaceutical ingredients. The powders ( | 2010-10-21 |